NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Soligenix, Inc. (SNGX) Stock Analysis

Soligenix, Inc. (SNGX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

SNGX

$0.38

$0.00 (0.00%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SNGX with… →

SNGX Key Statistics

As of Sep 4, 2026
Trading
Open
$0.38
Previous Close
$0.38
52-Week Range
0.28–3.07
Volume
108.80K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.92
Valuation
Market Cap
$8.27M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.72
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$11.08M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
21.77M
1-Year Return
−87.50%
Dividend and dates
Avg Volume
668.73K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

SNGX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−71.64%
2025−50.37%
2024−77.80%
2023−88.74%
2022−31.82%
2021−48.44%
2020−11.72%
2019+68.60%
2018−61.26%
2017−1.33%
2016 (partial year)−63.11%

As of September 4, 2026.

SNGX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$11.08M—
2024$0.00−$8.27M—
2023$0.00−$6.14M—
2022$250.00K−$13.80M−5519.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00$0.00−$11.85M−$11.08M—
2024$0.00−$119.37K−$9.46M−$8.27M—
2023$0.00−$742.05K−$7.67M−$6.14M—
2022$250.00K−$300.82K−$14.11M−$13.80M−5519.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

SNGX Valuation vs Biotechnology Median

Median of 656 stocks
MetricSNGXBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Soligenix, Inc. (SNGX) carries a market capitalisation of $8.27M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 13.

The 52-week range on file runs from $0.28 to $3.07. SNGX last closed at $0.38 on September 4, 2026. The close was unchanged from the previous session. The latest close sits 35.71% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $11.08M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −0.72.

Across the 4 fiscal years on file, revenue moves from $250.00K in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The trailing one-year price return is −87.50%. Measured over 10 years, that is −56.41% a year compounded. The reported beta is 1.92. Daily returns over the trailing 10 years annualize to a volatility of 144.54%.

Growth & Income

The record shows no dividend for SNGX.

Across the complete calendar years on file, 2019 returned +68.60% and 2023 returned −88.74%. Of the 9 complete calendar years on file, 1 finished higher. So far in 2026 the price is −71.64%.

Peer Comparison

Soligenix, Inc. (SNGX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Soligenix, Inc. SNGX $8.27M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Soligenix, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Soligenix, Inc.

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in Phase 3 clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX945, an IDR technology that is in Phase 2a study to treat aphthous ulcers in Behçet's disease; and SGX302, an IDR technology, which is in Phase 2a study for the treatment of mild-to-moderate psoriasis. Its Public Health Solutions segment engages in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a, 1b, and 1c clinical trials; SGX943, a therapeutic candidate in preclinical studies for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; CiVax, a vaccine candidate for the prevention of COVID-19; and vaccine programs that target filoviruses, such as Marburg and Ebola. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in September 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

Visit website →